

# H3K27M Primary Antibody

Clone: H3K27M/12537R (Rabbit Monoclonal)

**Localization** – Nuclear

**Host Species** – Rabbit

**Ig Class** – IgG

## Intended Use

This antibody is designed for the specific localization of H3K27M in formalin-fixed, paraffin-embedded (FFPE) tissue sections.

## Storage & Handling

Store RTU Vial at 2-8°C. Fresh dilutions for concentrated antibodies, if required, should be prepared prior to use and are stable for up to one day at room temperature (20-26°C).

ORDERING INFORMATION	
CATALOG#	DESCRIPTION
DH425-01C	0.1 ML Concentrated Antibody Vial
DH425-05C	0.5 ML Concentrated Antibody Vial
DH425-1C	1 ML Concentrated Antibody Vial
DH425-3R	3 ML Ready-to-Use Antibody Vial
DH425-6R	6 ML Ready-to-Use Antibody Vial
DH425-12R	12 ML Ready-to-Use Antibody Vial

## Working Principle

IHC is a two-step process wherein the primary antibody binds to the antigen of interest and that binding is detected by a chromogen. The primary antibody may be used in IHC using manual techniques or any Automated Staining System. Positive and negative controls should always be run simultaneously with all patient specimens.

## Product Description

H3K27me3 is an epigenetic histone modification catalyzed by the Polycomb Repressive Complex-2 (PRC2), with EZH2 as its catalytic subunit responsible for trimethylation of lysine-27 on histone H3. Mutations in EZH2 can lead to abnormal H3K27me3 accumulation and transcriptional repression of tumor suppressor genes.

Histone demethylases KDM6A and KDM6B remove this mark and may be inactivated in several malignancies. Loss of H3K27me3 expression is characteristic of many malignant peripheral nerve sheath tumors (MPNSTs) and can also occur in other neoplasms, sometimes showing heterogeneous expression.

## Material Supplied

H3K27M antibody is affinity purified and diluted in PBS, pH 7.4, containing 1% BSA and 0.09% sodium azide.

## Material required But Not Supplied

- Xylene
- Isopropyl alcohol
- Positive charged slides
- Wash Buffer
- DI Water
- Antigen retrieval buffers
- Blocking Reagents
- Detection System
- Control Tissues
- Hematoxylin
- Mounting media
- Cover glass

## Working Reagent Procedure

- Ready-to-Use antibodies have been optimized for use with the recommended protocols and should not require further dilution.
- Concentrated antibodies must be diluted in accordance with the recommended protocol.

## Recommended Protocol

Refer the following table for the details on specific recommended protocol for this antibody.

<b>Control Tissue</b>	Normal and most tumor tissues contains intact nuclear H3K27me expression	<b>Antibody Incubation Time</b>	30-60 Minutes at RT
<b>Dilution factor</b>	<b>1:20-50</b> (Antibody Diluent: DH144)	<b>Retrieval Pre-treatment</b>	<b>Tris-EDTA based HIER</b> (AR9 Buffer: DH020)

## Precautions

*This product should be used by qualified and trained professional users only.*

Avoid microbial contamination of reagents to minimize non-specific staining. Never pipette reagents by mouth. Avoid contact of reagents and specimens with skin. If reagents or specimens come into contact with sensitive area, wash with sufficient amounts of water. Dispose of the unused reagents. This kit contain sodium azide at concentrations of less than 0.1%. Sodium azide is not classified as a hazardous chemical at these concentrations, but proper handling protocols should be observed. For more information on product hazards, precautions and waste disposal, *Material Safety Data Sheets* are available upon request.

## Limitations

Improper tissue handling and processing prior to immunostaining can lead to inconsistent results. Variations in embedding and fixation or the nature of the tissue may lead to variations in results. Endogenous peroxidase activity or pseudo peroxidase activity in erythrocytes and tissue biotin may result in non-specific staining based on the detection system employed. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive with horseradish peroxidase systems. Improper counterstaining and mounting may compromise the interpretation of results. Interpretation of the staining result is solely the responsibility of the user. Experimental results should be confirmed by a medically-established diagnostic product or procedure. Evaluation must be performed by a qualified pathologist.

## Troubleshooting

For Technical Support contact us at +91 - 7506501122 or [info@dygnova.com](mailto:info@dygnova.com) or your local distributor to report unusual staining.

Doc No: DH/DS/INS423Rev.00

	Manufacturer Details		Use by Date	<b>LOT</b>	Lot/Batch Number
	Manufacturing Date		Consult Instructions for Use	<b>REF</b>	Catalogue Number
	Temperature Limits		Sufficient for 'n' assays / tests	<b>IVD</b>	In-vitro Diagnostic Medical Device